Mercedes Brunet Serra

List of Publications by Citations

38 papers	1,100 citations	16 h-index	33 g-index
41 ext. papers	1,454 ext. citations	4.2 avg, IF	3.62 L-index

#	Paper	IF	Citations
38	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. *Therapeutic Drug Monitoring*, **2009**, 31, 139-52	3.2	347
37	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
36	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. *Hepatology*, **2018**, 67, 1683-1694	11.2	83
35	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. *Nephrology Dialysis Transplantation*, **2009**, 24, 2269-76	4.3	69
34	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. *Therapeutic Drug Monitoring*, **2016**, 38 Suppl 1, S1-20	3.2	57
33	Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. *Transplantation*, **2006**, 81, 541-6	1.8	52
32	Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. *Clinical Chemistry*, **2003**, 49, 1891-9	5.5	46
31	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. *British Journal of Clinical Pharmacology* , **2017**, 83, 2636-2650	3.8	36
30	Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. *Transplantation*, **2010**, 89, 994-1000	1.8	34
29	Role of age and comorbidities in mortality of patients with infective endocarditis. *European Journal of Internal Medicine*, **2019**, 64, 63-71	3.9	20
28	T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. *Molecular Diagnosis and Therapy*, **2007**, 11, 247-56	4.5	18
27	A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. *Translational Psychiatry*, **2019**, 9, 177	8.6	17
26	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. *International Immunology*, **2016**, 28, 55-64	4.9	17
25	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, **2021**, 43, 150-200	3.2	17
24	Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. *Journal of Inherited Metabolic Disease*, **2021**, 44, 961-971	5.4	17
23	Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. *Clinical Biochemistry*, **2014**, 47, 223-7	3.5	16
22	Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in Adult Liver Transplant Recipients. *Frontiers in Immunology*, **2019**, 10, 873	8.4	12

21	Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection. *Transplantation*, **2018**, 102, 1075-1084	1.8	10
20	T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection. *Therapeutic Drug Monitoring*, **2016**, 38 Suppl 1, S21-8	3.2	10
19	High proportion of CD95(+) and CD38(+) in cultured CD8(+) T cells predicts acute rejection and infection, respectively, in kidney recipients. *Transplant Immunology*, **2016**, 34, 33-41	1.7	8
18	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 829-836	5.1	7
17	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. *Therapeutic Drug Monitoring*, **2020**, 42, 665-670	3.2	6
16	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1125-7	5.1	5
15	Pharmacodynamic Monitoring of mTOR Inhibitors. *Therapeutic Drug Monitoring*, **2019**, 41, 160-167	3.2	5
14	MicroRNAs 155-5p, 122-5p, and 181a-5p Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. *Liver Transplantation*, **2020**, 26, 1275-1286	4.5	4
13	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. *International Journal of Hematology*, **2017**, 105, 497-505	2.2	4
12	Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, 2585-2585	2.2	3
11	Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. *Liver International*, **2020**, 40, 931-946	7.9	3
10	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. *PLoS ONE*, **2021**, 16, e0245880	3.7	3
9	A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. *European Journal of Cancer*, **2021**, 146, 87-94	7.5	2
8	Monitoring of Donor-Derived Cell-Free DNA by Short Tandem Repeats: Concentration of Total Cell-Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. *Liver Transplantation*, **2021**,	4.5	2
7	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. *Liver International*, **2020**, 40, 2476-2488	7.9	1
6	Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 3619-3624	5.1	1
5	Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review. *Infectious Diseases and Therapy*, **2021**, 10, 1055-1064	6.2	1
4	Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation. *Expert Review of Clinical Pharmacology*, **2021**, 1-13	3.8	0

3	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. *British Journal of Clinical Pharmacology*, **2021**, 87, 3851-3862	3.8	0
2	Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay. *Clinical Toxicology*, **2021**, 59, 500-505	2.9	0
1	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. *Clinical Immunology*, **2021**, 229, 108792	9	0